Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,811 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).
Fukuda M, Kitazaki T, Ogawara D, Ichiki M, Mukae H, Maruyama R, Nakagaki N, Shimada M, Ikeda T, Kishimoto J, Harada T, Seto T, Ebi N, Takayama K, Okamoto I, Ichinose Y, Sugio K. Fukuda M, et al. Among authors: ikeda t. Lung Cancer. 2019 Jun;132:1-8. doi: 10.1016/j.lungcan.2019.01.008. Epub 2019 Apr 5. Lung Cancer. 2019. PMID: 31097081 Clinical Trial.
Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer.
Fukuda M, Nakamura Y, Kinoshita A, Soejima Y, Yamaguchi H, Ikeda T, Izumikawa K, Takatani H, Fukuda M, Soda H, Hayashi N, Tsukamoto K, Oka M, Kohno S. Fukuda M, et al. Among authors: ikeda t. Cancer Chemother Pharmacol. 2012 Nov;70(5):645-51. doi: 10.1007/s00280-012-1952-5. Epub 2012 Aug 22. Cancer Chemother Pharmacol. 2012. PMID: 23010852 Clinical Trial.
Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.
Motoshima K, Nakamura Y, Sano K, Ikegami Y, Ikeda T, Mizoguchi K, Takemoto S, Fukuda M, Nagashima S, Iida T, Tsukamoto K, Kohno S. Motoshima K, et al. Among authors: ikeda t. Cancer Chemother Pharmacol. 2013 Dec;72(6):1299-1304. doi: 10.1007/s00280-013-2307-6. Cancer Chemother Pharmacol. 2013. PMID: 24121455 Clinical Trial.
A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
Ikeda T, Fukuda M, Nakamura Y, Kinoshita A, Senju H, Nakano H, Kitazaki T, Ogawara D, Taniguchi H, Motoshima K, Yamaguchi H, Nakatomi K, Shimada M, Nagashima S, Tsukamoto K, Kohno S; Nagasaki Thoracic Oncology Group. Ikeda T, et al. Cancer Chemother Pharmacol. 2014 Sep;74(3):497-502. doi: 10.1007/s00280-014-2527-4. Epub 2014 Jul 18. Cancer Chemother Pharmacol. 2014. PMID: 25034978 Free article. Clinical Trial.
Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Mizoguchi K, Nakamura Y, Sano K, Sato S, Ikegami Y, Motoshima K, Takemoto S, Ogawara D, Senju H, Sugasaki N, Ikeda T, Yamaguchi H, Nakatomi K, Fukuda M, Izumikawa K, Mukae H. Mizoguchi K, et al. Among authors: ikeda t. Cancer Chemother Pharmacol. 2016 Aug;78(2):377-82. doi: 10.1007/s00280-016-3097-4. Epub 2016 Jun 23. Cancer Chemother Pharmacol. 2016. PMID: 27339148 Clinical Trial.
6,811 results